Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Vasc Surg ; 63(5): 1371-4, 2016 May.
Article in English | MEDLINE | ID: mdl-27109797

ABSTRACT

We present three patients with dissecting and saccular aneurysms affecting the cervical carotid and vertebral arteries treated with flow diversion using the Pipeline Embolization Device (ev3 Endovascular Inc/Covidien, Plymouth, Minn). The device was successfully deployed in all three patients without complication. Follow-up imaging studies at 8 to 18 months revealed complete occlusion of all three aneurysms. This device may be a valuable alternative to stent-graft devices in the treatment of cervical aneurysms since it is delivered through a microcatheter that is better able to negotiate tortuous anatomy of cervical carotid and vertebral arteries.


Subject(s)
Aortic Dissection/therapy , Carotid Artery Diseases/therapy , Embolization, Therapeutic/instrumentation , Vascular Access Devices , Vertebral Artery Dissection/therapy , Aortic Dissection/diagnostic imaging , Aortic Dissection/physiopathology , Angiography, Digital Subtraction , Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/physiopathology , Cerebral Angiography/methods , Equipment Design , Female , Humans , Male , Middle Aged , Regional Blood Flow , Treatment Outcome , Vertebral Artery Dissection/diagnostic imaging , Vertebral Artery Dissection/physiopathology
2.
J Neurosurg Pediatr ; 11(6): 635-42, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23601015

ABSTRACT

OBJECT: The objective of this investigation was to review the clinical characteristics of recurrent CSF shunt infections in a large pediatric neurosurgical practice and to assess the safety and efficacy of reusing original ventricular entry sites for external ventricular drainage during treatment of infections and for subsequent reinsertion of shunts. METHODS: Prospectively accrued clinical data on all patients treated at Children's Hospital Colorado for CSF shunt infections within a 10.5-year span were retrospectively investigated. RESULTS: One hundred twenty-one consecutive cases of CSF shunt infection met inclusion criteria. Recurrent shunt infection attributable to the management of these infections occurred in 14 cases (11.6%). Three recurrent infections were with their original organisms, 7 were organisms different from the original organisms, and 4 were indeterminate. CONCLUSIONS: Half or more of recurrent shunt infections were with organisms different from the original organism, and hence were new-type infections introduced during the management of the original infections. Incomplete eradication of original pathogens accounted for 3 (21.4%) of the 14 recurrent infections. Reusing recently infected or contaminated ventricular entry sites, both for CSF drainage during treatment and for implantation of new shunts, was as safe, with regard to risk of recurrent infection, as switching to new entry sites. Prior evidence of shunt infection is not, alone, a sufficient reason to change to a previously well-functioning site, and reuse of contaminated ventricular entry sites avoids all risks associated with making new ventricular entries.


Subject(s)
Cerebrospinal Fluid Shunts/adverse effects , Prosthesis-Related Infections/etiology , Prosthesis-Related Infections/prevention & control , Staphylococcal Infections/etiology , Staphylococcal Infections/prevention & control , Adolescent , Child , Child, Preschool , Colorado/epidemiology , Drainage , Female , Humans , Infant , Infant, Newborn , Male , Medical Records , Prosthesis-Related Infections/epidemiology , Prosthesis-Related Infections/microbiology , Recurrence , Retrospective Studies , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Staphylococcus aureus , Staphylococcus epidermidis , Time Factors , Treatment Outcome , Young Adult
3.
Clin Transplant ; 24(2): 223-8, 2010.
Article in English | MEDLINE | ID: mdl-19659514

ABSTRACT

Evidence suggests that West Nile virus (WNV) neuroinvasive disease occurs more frequently in both solid organ and human stem cell transplant recipients. The effect of concomitant anti-B-cell therapy with rituximab, a CD20(+) monoclonal antibody, on WNV infection in this population, however, has not been reported. We describe a case of a patient with alpha-1-antitrypsin deficiency who underwent single lung transplantation in 2005 and was maintained on tacrolimus, cytoxan and prednisone. More recently, she had received two courses of rituximab for recurrent A2-A3 grade rejection with concomitant capillaritis and presented six months later with rapid, fulminant WNV meningoencephalitis. Her diagnosis was made by cerebrospinal fluid (CSF) PCR but serum and CSF WNV IgM and IgG remained negative. She received WNV-specific hyperimmune globulin (Omr-Ig-Am) through a compassionate protocol. She experienced a rapidly progressive and devastating neurological course despite treatment and died three wk after onset of her symptoms. Autopsy revealed extensive meningoencephalomyelitis.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunocompromised Host , Immunologic Factors/therapeutic use , Lung Transplantation , Meningoencephalitis/virology , West Nile Fever/immunology , Antibodies, Monoclonal, Murine-Derived , B-Lymphocytes/immunology , Disease Progression , Fatal Outcome , Female , Graft Rejection/drug therapy , Humans , Immunoglobulins/therapeutic use , Lung Transplantation/immunology , Meningoencephalitis/immunology , Middle Aged , Rituximab , West Nile Fever/diagnosis , West Nile Fever/drug therapy , alpha 1-Antitrypsin Deficiency/surgery
4.
Mol Cell Proteomics ; 1(8): 553-60, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12376570

ABSTRACT

Proteomics is a field of study directed toward providing a comprehensive view of the characteristics and activity of every cellular protein. Rapid innovations in the core technologies required to characterize proteins on a global scale are poised to bring about a comprehensive understanding of how dynamic changes in protein expression, post-translational modification, and function affect complex signaling and regulatory networks. These advances have significant implications for understanding the multitude of pathways that govern behavior and cognition and the response of the nervous system to injury and disease.


Subject(s)
Nervous System/metabolism , Neurosciences , Proteins/analysis , Proteomics , Animals , Genome , Genome, Human , Humans , Isotopes/metabolism , Molecular Structure , Nervous System/pathology , Neurodegenerative Diseases/metabolism , Proteins/chemistry , Proteins/metabolism
5.
Adv Exp Med Biol ; 513: 41-86, 2002.
Article in English | MEDLINE | ID: mdl-12575817

ABSTRACT

Neuronal viability is maintained through a complex interacting network of signaling pathways that can be perturbed in response to a multitude of cellular stresses. A shift in the balance of signaling pathways after stress or in response to pathology can have drastic consequences for the function or the fate of a neuron. There is significant evidence that acutely injured and degenerating neurons may die by an active mechanism of cell death. This process involves the activation of discrete signaling pathways that ultimately compromise mitochondrial structure, energy metabolism and nuclear integrity. In this review we examine recent evidence pertaining to the presence and activation of anti- and pro-cell death regulatory pathways in nervous system injury and degeneration.


Subject(s)
Cell Death/physiology , Cell Survival/physiology , MAP Kinase Signaling System/physiology , Neurons/physiology , Calpain/metabolism , Caspase Inhibitors , Caspases/metabolism , Cell Nucleus/metabolism , DNA Damage , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Mitochondria/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism , Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptor, Nerve Growth Factor , Receptors, Nerve Growth Factor/metabolism , Receptors, Tumor Necrosis Factor/metabolism , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...